Treatment of decrease in hemoglobin levels by Unani medicine Majoon Khabs-ul-Hadeed

Phase 3

Not yet recruiting

• Conditions: Other iron deficiency anemias,

• Registration Number: CTRI/2020/07/026569
• Lead Sponsor: Central Council for Research in Unani Medicine CCRUM New Delhi

Brief Summary

This study is designed as a multicentric open trial in patients with **Sū’ al-Qinya (Iron deficiency Anaemia)****.** After screening, Patients will be enrolled if they satisfy inclusion and exclusion criteria. The patients will be treated with Unani pharmacopoeial formulation *Majoon Khabs-ul-Hadeed*5 gm daily orally with water after meals for 12 weeks.  The patients will be assessed at 0, 4, 8, 12 weeks. This includes subjective assessment of general well being and physical examination . The total duration of treatment will be 12 weeks. Laboratory parameters for safety assessment will be conducted at baseline and on completion of the protocol therapy.

**Composition of****Majoon Khabs-ul-Hadeed**

| | | | |

| --- | --- | --- | --- |

|**S. No.**

**Ingredients**

**Botanical Name**

**Quantity**

|1.

Tukhm Hummaz Biryan

*Rumex vesicarius* L.

10 g

|2.

Habb-ul Aas Biryan

*Myrtus communis* L.

10 g

|3.

Post Halela Zard

*Terminalia Chebula*

10 g

|4.

Aamla Biryan

*Phyllanthus emblica*

10 g

|5.

Post Beekh Anjabar

*Fumaria parviflora*

10 g

|6.

Halela Siyah

*Terminalia Chebula*

10 g

|7.

Busud

*Corallium rubrum*

10 g

|8.

Kehruba

*Vateria indica gum*

10 g

|9.

Khabs-ul-Hadeed Mudabbar

*Iron Oxide*

20 g

|10.

Rubb Seb Shireen

*Malus domestica*

100 g

|11.

Sharbat e Behi

*Cydonia oblonga*

150 g

|12.

Asl or Qand Safaid

*Honey*

150 g

Detailed Description

Not available

Study Timeline

• Study Start: 2020-07-19
• Last Update Posted: 2020-09-07

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

Patients having mild (10.0-11.9 g/dl) to moderate (7.0-9.9 g/dl) Anaemia.

Exclusion Criteria

• Patients having severe Anaemia (below 7gm/dl) 2.
• Patients with excessive bleeding e.g. bleeding piles, menorrhagia, metrorrhagia etc 3.
• Known cases of chronic diseases on long term treatment.
• Patients with concurrent serious hepatic, cardiac, renal dysfunction.
• Pregnant and lactating women.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improvement in signs and symptoms of Sū’ al-Qinya (Iron deficiency Anaemia)	12 weeks

Secondary Outcome Measures

Name	Time	Method
Haematological and biochemical assessment for safety assessment	Investigations will be done at 0, 4, 8, 12 weeks

Trial Locations

Locations (4)

Central Research Institute of Unani Medicine (CRIUM); 🇮🇳 Lucknow, UTTAR PRADESH, India

Clinical Research Unit (CRU); 🇮🇳 Nimar, MADHYA PRADESH, India

Regional Research Centre (RRC); 🇮🇳 Allahabad, UTTAR PRADESH, India

Regional Research Institute of Unani Medicine (RRIUM); 🇮🇳 Kolkata, WEST BENGAL, India

Central Research Institute of Unani Medicine (CRIUM)

🇮🇳Lucknow, UTTAR PRADESH, India

Dr Mohd Nafees Khan

Principal investigator

9140705710

mnkccrum@yahoo.com